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Exposure  to  Neisseria  meningitidis  may  result  in  either  asymptomatic 
infection (carriage) or acute disease. Early studies indicated that acute menin- 
gococcal disease probably occurs about 2 wk after acquisition of the organism 
(1). Regardless of whether individuals become carriers or develop acute disease, 
they develop humoral antibodies to a  variety of antigens,  including the group- 
specific polysaccharide (2, 3), the protein serotype antigen  (STA), 1 and lipopoly- 
saccharide  (LPS)  (4).  Group-specific  polysaccharide  antibodies  peak  approxi- 
mately 2 wk after onset of acute disease (5, 6),  but the nature of the immune 
response  to the  STA  and  LPS antigens  resulting  from carriage  or disease  is 
unknown. 
There  is  no  entirely  satisfactory  animal  model  simulating  meningococcal 
disease in man,  although several have been studied for their ability to predict 
the  effectiveness of vaccines  or serum  therapy.  The  mouse-mucin  model de- 
scribed by Miller and Castles in  1936  (7) and later standardized  by Branham 
and Pittman  (8, 9) was one of the first models for study of immune protection. 
Study  of the  immune  response  resulting  from  mouse  infection  is  difficult 
because  the  effects  of  mucin  on  the  immune  response  and  clearance  are 
unknown.  The  rabbit  has  also  been  used,  but  massive  doses  of organisms 
injected intracranially  wererequired to cause meningitis-like  disease (10). The 
chick embryo model was used to study passive protection against meningococcal 
infection (11-14), but active immunization  is not possible. 
In these studies,  the guinea pig implant  model of Arko (15) was examined. 
This model proved useful because (a) the animals could be actively immunized, 
(b)  useful amounts  of serum  from individual  animals  were obtained,  (c) the 
induced meningococcal infections were not lethal, thus permitting rechallenge, 
and  (d)  localization  of  the  infection  permitted  quantitation  of  organisms 
present.  As  long  as  no  attempt  is  made  to  study  the  pathophysiology  in 
relation to human disease, the guinea pig spring implant model is satisfactory. 
The purpose of our investigation was to examine the specificity and duration 
of the  immune  response  to  meningococcal  infection  and  to  determine  the 
* A  portion  of this investigation was conducted at The Rockefeller University and was 
supported by the U. S. Army Medical Research and Development Command, Research Contract, 
DADA  17-70-C-0027,  and by Public Health Service  grant NS-11863 from the National Institute  of 
Neurological Diseases and Stroke, National Institutes  of  Health, Bethesda, Md. 20014. 
i  Abbreviations  used in this paper:  BHIA, brain heart infusion  agar;  ELISA, enzyme-linked 
immunosorbant assay;  LPS, lipopolysaccharide;  STA, serotype  antigen. 
THE  JOURNAL  OF EXPERIMENTAL  MEDICINE  • VOLUME  147,  1978  619 620  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE.  II 
protective  effects of the  primary  infection  upon subsequent challenge.  These 
investigations will show that meningococci readily infect the implanted cham- 
bers inducing both group- and type-specific protection. 
Materials  and Methods 
Strains  and  Growth  Conditions.  Meningococcal group  B  strains  M986,  M990,  M1080,  and 
M136 have been characterized (16,  17). The group B type 2 strain $946 and group Y type 2 strain 
S1975  were  received from  Dr.  Harry  Feldman,  Upstate  Medical  Center,  Syracuse,  N.  Y.  The 
group C strains 60E and 138I were obtained from the late Dr. Malcolm Artenstein, Walter Reed 
Army Medical Center, Washington, D. C. For animal challenge, the organisms were grown into 
log phase (6 h) on brain heart infusion agar (BHIA, Difco Laboratories, Detroit, Mich.) at 36°C in 
candle jars. The organisms were diluted in Hanks' balanced salt solution to 80% transmission at 
540 nm in a  Coleman Jr.  spectrophotometer (3  ×  10S/ml).  After challenge, fluid aspirated from 
the guinea pig chambers was diluted 10  -1 and 10 -3 in Hanks' balanced salt solution and cultured 
onto  BHIA.  For  some  experiments,  blood  and chamber  fluid  were  cultured  onto  serum  agar 
plates containing 6%  horse anti-group  B  serum.  On these plates,  group  B  meningococci were 
identified by a  precipitin halo surrounding the colonies after 24-48 h growth at 36°C. 
Guinea Pig Model.  Stainless steel springs were implanted into 400-600 g Hartley (Rockefeller 
University, New York) and NIH-Hartley guinea pigs as described by Arko (15).  The 1 cm  x  2.5- 
cm  spring  chambers  were  prepared  from  22  B&S  gauge  surgical  steel  (Perkin-Elmer  Corp., 
Maywood, Ill.) and implanted subcutaneously on one or both sides of the animals through a  mid- 
line incision on the back. Log phase meningococci were injected either intravenously or directly 
into the chambers 10-12 clays after implantation. The chambers were usable up to 3 wk after the 
initial challenge, after which they failed to allow meningococcal growth. Chambers were always 
sampled 2 days after challenge and various days thereafter by removing 0.1 ml fluid with a  1 ml 
disposable  syringe.  Animals  were  considered  infected  if on  day  2  they  had  more  than  100 
organisms/milliliter  in their  subcutaneous  chambers. 
Most animals were bled from the heart for antibody determinations, and some from an ear 
vein for  blood culture. 
Serological  Methods.  The enzyme-linked  immunosorbant assay (ELISA) was used  to  measure 
serotype antibody by the technique of  Engvall and Perlmann (18)  with slight  modification (4). 
Indirect  hemagglutination  was performed as  described  (19),  with  purified  meningococcal  polysac- 
charides. 
Results 
Implantation of stainless steel springs into guinea pigs provided an artificial 
subcutaneous  tissue  cavity  in  apparent  free  association  with  the  animals' 
humoral and cellular defense mechanisms. Preliminary experiments were done 
to characterize the infectivity and dose required to induce a  100% infection rate 
(IDloo).  Results  of three  such  infectivity  assays  are  shown  in  Table  I.  The 
organisms used for infectivity experiments were not passaged through guinea 
pigs to  increase their  virulence.  A  challenge  dose of approximately  105 orga- 
nisms  for the  following experiments  was chosen  to  ensure  100%  infection  in 
nonimmune  animals. 
Duration  of infection was determined  for several different serotype strains 
(Table II). Most strains examined persisted for several days at approximately 5 
×  l0  s organisms/ml  of chamber  fluid,  even though  within  24  h  of infection, 
large numbers of polymorphonuclear leukocytes were present in Gram-stained 
smears  of the  fluid.  The  number  of organisms  in  the  chambers  remained 
relatively constant for 4-6 days, followed by elimination of infection by approx- 
imately  day  12.  Three  group  Y  strains  (S-1975,  S-1255,  and  S-1161)  were CARL  E.  FRASCH  AND  JOAN  D.  ROBBINS 
TABLE  I 
Infectivity of Different Group B Strains for Spring Implants in Guinea Pigs 
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No. organisms in-  Organisms/ml  Animals infected/ 
Animal set  Strain  Serotype  jected  day 2*  challenged 
15  M1080  1  2 x 104  2 × 10  ~  3/3 
16  2 x 103  5 x 104  2/3 
17  2 × 102  1 × 104  2/3 
18  2 × 10  ~  5 x 10  ~  2/3 
C  S-946  2  3  x  105  1  x  107  3/3 
4  4  x  104  2  x  10  v  4/4 
5  4  x  10  s  3  x  10  t  4/4 
6  4  x  102  9  x  106  4/4 
19  M-990  6  4  x  105  1  x  107  3/3 
20  4  x  104  2  x  107  3/3 
21  4  x  l0 s  2  x  107  3/3 
22  4  x  102  2  x  107  2/3 
* Average number of  organisms/milliliter in chamber was determined 2 days postinfection and 
calculated based upon those infected. 
TABLE II 
Duration  of Infection  after Challenge by Different Meningococcal Strains 
Animal  Strain  Serogroup,  Challenge 
set  serotype  dose 
No.  infected/challenged on days  (Average organisms/milliliter) 
2  4  6  8  10  12  14 
15  M1080  B,  1  2  ×  104  3/3  -*  3/3  -  -  0/3  - 
(2  x  l0  s)  (2  x  104) 
23  S-946  B, 2  5  ×  10  ~  4/4  -  4/4  -  -  2/4  - 
(7 ×  10  ~)  (1  x  107)  (4  ×  10  ~) 
12  138I  C, 2  2  ×  10  e  4/4  -  -  4/4  1/4  - 
(4 ×  10  ~')  (2  x  10  ~)  (6  x  l0  s) 
30  S-1975  Y, 2  4  x  105  4/4  3/4  3/4  -  1/4  -  0/4 
(5  x  lO  s)  (2  x  10  4)  (1  x  10  4)  (3  x  I0  4) 
20  M990  B, 6  4  x  104  3/3  -  2/3  -  -  0/3  - 
(2  x  107)  (7  ×  102) 
11  M136  B, 11  2  x  l0  s  3/3  -  -  3/3  0/3  - 
(8  x  l0 s)  (4  x  10  ~) 
* Not done. 
examined and all persisted as long as other strains, but never at concentrations 
greater than  104 organisms/milliliter. 
For protection studies, we initially considered rechallenge of animals simul- 
taneously  with  two  different  meningococcal  strains  injected  into  two  widely 
spaced subcutaneous chambers as reported for gonococci (20, 21). The feasibility 
of this technique  was tested by injecting  105 organisms of strain  S-946  (group 
B, type 2) into one chamber 14 days after implantation of 2 chambers. Contrary 
to our expectations, both chambers were equally infected (10  T organisms/ml)  2 
days  after  challenge.  It  was  clear  from  this  experiment  that  simultaneous 
challenge with different strains was not feasible. To determine whether hema- 
togenous spread could account for these results, sets of animals,  each with two 
implants,  were  challenged  with  S-946  either  intravenously,  or  directly  into 
their  right  chambers  (Table  III).  1  day  after  challenge,  10  meningococci/ 
milliliter  were  cultured  from  the  blood  of two  of eight  animals  challenged 622  PROTECTION  AGAINST GROUP B MENINGOCOCCAL DISEASE. II 
TABLE III 
Role of the Spring Implant as a Nidus for Initiation of Meningococcal Infection by 
Group B  Type 2 Strain S-946 
Challenge  Infection of  chambers 
Animal sets  Days poet  Right  LeR  Blood in- 
Dose  Route  challenge  fection 
Infected/  Average orga-  Infected/  Average orga- 
challenged  nism/ml  challenged  nism/ml 
35, 36  2  ×  l0  s  i.v.  1  6/8  3  ×  105  6/8  2  x  10  ~  2/8 
2  7/8  9  x  106  8/8  1  ×  107  2/8 
6  8/8  4  x  10  ~  7/8  3  x  10  ~  - 
37, 38  4 x  I0  s  Chamber  (right)  1  8/8  6  x  tO  ~  6/8  1 x  I0  ~  018 
2  6/8  3  x  I0  ~  518  1 x  i0  ~  0/8 
6  6/8  5 ×  106  6/8  2  ×  1(~  - 
intravenously,  and  by  day  2  all  had  infected  chambers.  Of eight  animals 
challenged  directly  in  the  right  chamber,  six  became  infected  in  the  left 
chamber. Thus, the chamber implant probably serves as a  nidus in which an 
infection can  be  established  by  hematogenous spread.  Direct  subcutaneous 
extension  between  chambers  is  an  alternative  or  second  mode  of  spread. 
Support for this possibility is our finding that greatly reduced transfer between 
chambers occurred when the  right  chamber  was  not challenged until 4  wk 
after implantation (chambers do not fibrose  as  rapidly in unchallenged ani- 
mals). 
Animals were examined for their resistance to homologous reinfection with a 
challenge dose of approximately 100 times the MID10o, given 13-90  days after 
clearance of the primary infection (Table  IV).  All animals were resistant to 
homologous rechallenge and they remained so for at least 3 mo. 
The accelerated clearance of meningococci 8-10 days after infection suggested 
immune clearance. To determine the relationship between clearance of infection 
and  appearance  of humoral  antibody,  guinea  pigs  were  prebled  and  then 
infected with strain S-946. Cultures and sera were obtained at intervals until 
the  infection  was  eliminated  (Fig.  1).  Coincident  with  elimination of the 
infection was a  rise in serotype antibody. Although antibody levels on day 14 
were low, they continued to rise after the infection cleared (Fig. 2). Antibody to 
the group B polysaccharide as measured by indirect hemagglutination was also 
present by day 14. 
The  antibody response  to the type 1 and type 6  STAs  was determined by 
ELISA in two sets of animals, one infected with strain M1080 (B, type 1),  and 
the other with M990 (B, type 6). The results are shown in Fig. 2. Although the 
infections  were  eliminated  within  2  wk  in  both  groups  of animals,  their 
antibody levels did not peak until 4 wk later,  and by 4 mo the antibody had 
still  not returned to preinfection levels.  Cross-reactivity in  the  antibody re- 
sponse as measured by ELISA was observed previously in rabbit sera (22). 
Since disease-producing meningococci of several different groups  (B,  C,  Y, 
and  W135) may possess  serotype  2  antigen  (23),  it  was  important to  know 
whether the observed protection in the guinea pigs would prove to be group 
and/or type-specific. Sets of animals were initially infected with type 2 strains 
of groups  B,  C,  and Y,  and an additional set with a  group B  type 11  strain CARL  E.  FRASCH  AND  JOAN  D.  ROBBINS  623 
TABLE IV 
Resistance of Animals to Rechallenge with the Homologous  Meningococcal Strain 
Animal set  Challenge  Serogroup,  Challenge  Days after pri-  Animals in- 
strain  serotype  dose  mary infec-  fected/chal- 
tion*  lenged 
6  M986  B, 2  3  x  105  45  0/3 
6  S-946  B, 2  4  x  106  26  0/3 
23  S-946  B, 2  4  ×  105  90  0/3 
12  138I  C, 2  1  x  10  ~  13  0/4 
30  S-1975  Y, 2  1  x  108  17  0/4 
11  M136  B, 11  3  x  106  13  0/3 
* Number of  days after  clearance of  primary infection  at  time of  rechallenge. 
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FIo.  1.  Correlation of serotype antibody formation as measured by ELISA with elimina- 
tion of infection by strain S-946  (B, 2). 
(Table  V).  The challenge dose for all strains was approximately 6  ×  10  ~ log 
phase organisms, except for group Y, which was l0  s organisms, and was given 
3 wk after clearance of the primary infection. Animals initially infected with 
type 2 strains of groups  B,  C, or Y resisted rechallenge with type 2 strains, 
regardless of serogroup. There was also group-specific protection since animals 
infected with two different group B strains resisted rechallenge with one or two 
heterologous group B strains but did not resist reinfection by a  group C strain 624  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE.  II 
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FIG.  2.  Serotype antibody response as a  result of infection with group B  meningococcal 
strains.  (A)  Guinea  pigs  infected  at  zero  time  with  strain  M990  (B,  6).  Homologous 
antibody response to type 6 STA is solid line and cross reacting response to type 1 STA is 
broken  line.  (B)  Guinea  pigs infected with  strain  M1080  (B,  1).  Homologous antibody 
response to type 1 STA is broken line and cross reacting response to type 6 STA is solid 
line. The arrow on both A and B shows when the infections were eliminated. 
of heterologous  serotype.  Thus,  both  group-  and  type-specific protection  was 
observed. 
There was a marked difference in the course of infection observed in resistant 
and  nonresistant  animals.  Animals that  became  infected  upon  rechallenge 
with group C strain  60E had approximately  107 organisms/milliliter  at 2 days 
and the  infections persisted  10-12 days.  In contrast,  those animals  who were 
partially immune but became infected had only 102-103 organisms/milliliter  at 
day 2, the infection never persisting beyond day 4. 
We examined sera from animals infected with group B or group C strains to 
determine whether the observed group-specific protection was due to antibodies 
against the capsular polysaccharide (Table VI). There was a significant increase 
in anti-capsular antibody, the peak polysaccharide antibody response occurring 
much earlier than the response against the protein antigens  (see Fig. 2). 
Discussion 
In our previous study on passive protection against  group B  meningococcal 
infection in the chick embryo (13), both group-specific and type-specific protec- 
tion  were observed.  Moreover,  there  was  a  synergistic  effect between group- CARL  E.  FRASCH  AND  JOAN  D.  ROBBINS 
TABLE  V 
Specificity of Protection after Infection with Different Meningococcal Strains 
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Primary infection  Challenge with strain (group, type)* 
Animal  M986  S-1975 
Set  Strain (group,  No.  in-  (B,  2)  M990  M136  138I (C,  60E  (C,  (Y, 2) 
type)  fected  (B, 6)  (B, 11)  2)  NT) 
b  S-946  (B,  2)  3/35  0/35  ..... 
c  S-946  3/3  -  0/3  .... 
a  S-946  3/3  -  -  0/3  -  -  - 
4  S-946  4/4  -  -  -  1/4  -  - 
6  S-946  3/3  ....  3/3  - 
11  M136 (B,  11)  3/3  0/3  -  0/3  -  3/3  - 
12  138I (C,  2)  4/4  0/3  -  -  0/4  3/3  - 
30  S-1975 (Y,  2)  4/4  0/4  -  -  1/4  -  0/4 
* All animals were challenged with approximately 5  ×  i0  ~  log  phase organisms into  a chamber. 
5 Number infected/challenged  determined on day 2. 
TABLE  VI 
Antibody Response to the Capsular Polysaccharide as a Result of Infection in Guinea 
Pigs 
Animal set  No.  ani-  Infecting  Group,  type  Serum on 
mals  strain  week 
Mean titer against* 
B  C 
1  3  -  -  -  <2  <2 
15  3  M1080  B,  1  2  21  ±  9  5  ±  3 
6  9±7  2±2 
23  3  S-496  B, 2  2  37  ±  24  3  -+  1 
6  15  ±  15  1  -+  1 
12  4  138I  C,  2  1  1  ±  2  13  ±  5 
2  <2  11  ±  5 
* Titer  determined  by  indirect  hemagglutination of  sheep  erythrocytes  coated  with  purified 
polysaccharide. 
and type-specific antibody.  However,  this  model has  definite disadvantages: 
the  chick  embryo  cannot  be  actively  immunized,  and  it  lacks  an  active 
complement system (24) which is critical in immune defense against meningo- 
coccal disease (25, 26). We, therefore, looked for an animal model that could be 
actively immunized by either prior infection or vaccination. 
The guinea pig chamber model has been used to study Neisseria gonorrhoeae 
infection (15,  20,  27, 28), but N. meningitidis  infection of these chambers was 
not examined. Various materials have been used to establish artificial chambers 
for Neisserial infection of guinea pigs (15, 20, 27). We chose the stainless steel 
spring for implantation  because it allows the most freedom of interaction of 
host cellular and humoral immune mechanisms with the Neisseria,  whereas 
plastic chambers may become highly encapsulated and allow the establishment 
of persistent infections (27, 28). 
For  most  meningococcal strains  we  could  achieve  an  ID~0o with  10-1,000 
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(27,  29).  As we had observed in our chick embryo emperiments  (13),  group B 
serotype 2 strains  infected at a  lower challenge  dose and persisted in greater 
numbers  than  many  other  group  B  strains.  Three  group  Y,  type  2  strains 
required  much  higher  challenge  doses  and  the  number  of  organisms  per 
milliliter  in  the  chamber  at  days 2-4  were only  104  vs.  107 for  B,  2  strains, 
suggesting a  lower virulence of group Y  strains.  Calver et al.  (30) also found 
that a group Y strain had a  much higher LDso for iron-treated mice than A, B, 
or C  strains.  Therefore,  infection in these animal  models appears to correlate 
to  some extent  with  the  epidemiological  data  in  humans  because there  is  a 
strong  association of serotype 2 with  meningococcal disease  (31-33)  and  high 
carrier  rates  are often observed for group Y  organisms  in absence of group Y 
disease (34). 
Duration  of infection  after  inoculation  of stainless  steel  spring  implants, 
placed  in  animals  10-14  days previously,  was  comparable  for  meningococcal 
and gonococcal strains  (35).  Guinea pigs infected with various meningococcal 
strains  usually  cleared  their  infections  in  10-12  days.  Clearance  of infection 
correlated with appearance of serotype and serogroup antibody. In unpublished 
observations, we found that serotype antibody elicited by guinea pig infection 
was bactericidal in vitro. 
Resistance  to  reinfection  was  determined  with  a  single  challenge  dose, 
estimated to be approximately  100 times the uniformly infectious dose. Other 
investigators have reported using graded challenge doses given over a period of 
several  days  (20,  35).  This  latter  method  is  less  satisfactory  because  the 
preinfecting challenge doses may potentiate the apparent immunity to infection 
in already immunologically primed animals. 
Resistance of the guinea pigs to rechallenge after clearance of their primary 
infection  was  both  group-  and  type-specific.  The  levels  of serotype  antibody 
induced  as  a  result  of  infection  were  considerably  lower  than  those  after 
immunization with serotype vaccines, 2 yet both protected against meningococcal 
challenge. 
Summary 
A guinea pig subcutaneous chamber model was used to evaluate the specific- 
ity of the  immune  response  resulting  from Neisseria  meningitidis  infection. 
Small  numbers  of meningococci easily infected the  chambers.  The  infections 
persisted for 6-8 days with relatively high levels of organisms (105-10e/milliliter) 
in the chambers,  and were then rapidly eliminated and no organisms could be 
cultured beyond day 14.  Clearance  of infection correlated with appearance  of 
circulating  antibody.  Antibody against both the protein serotype antigen  and 
the capsular polysaccharide were induced as a result of meningococcal infection. 
The  group-specific polysaccharide  response  peaked  2-3  wk  after the  animals 
were  inoculated,  while  the  type-specific protein  response  peaked  at  5-6  wk. 
The  animals  were quite  resistant  to reinfection  with  either  the  homologous 
serogroup or serotype. 
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